Level of plasma fibronectin in patients with breast cancer.
Plasma fibronectin was determined by laser nephelometric immunoassay in two populations: healthy individuals and patients with metastatic or non-metastatic breast cancer. The results showed that the fibronectin concentration was higher in the patient group than in the healthy controls of similar age, with a significant difference (p less than 0.05). The patients who had metastatic breast cancer tended to show higher levels than those with no detectable metastasis, but such a difference was not statistically significant. Since fibronectin is sensitive to clinical events unrelated to the malignancy status, it does not seem suitable as a tumor marker.
Ruelland
A
A
Laboratoire de Biochimie Médicale, Hôtel-Dieu, Rennes, France.
Kerbrat
P
P
Clerc
C
C
Legras
B
B
Cloarec
L
L
D000293:Adolescent; D000328:Adult; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000097:blood* / Q000473:pathology; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging
D005353:Fibronectins